FDA Expedites Review of Roche's Tecentriq for Stage III Colon Cancer Treatment

The U.S. FDA has accepted Roche's application for Tecentriq, granting it Priority Review status for the treatment of stage III colon cancer. This combination therapy with chemotherapy targets specific genetic markers in patients. A decision is anticipated by October 9, 2026, potentially establishing a new standard of care for patients facing a high risk of relapse.